RecruitingPhase 2NCT06659705

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)

Sponsor

Institut Curie

Enrollment

35 participants

Start Date

Dec 2, 2025

Study Type

INTERVENTIONAL

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Summary

Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening. In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process. All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared. Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new PET scan imaging agent called FAPI to see if it can detect pancreatic cancer earlier or more accurately than standard imaging. FAPI targets a protein found on cancer-associated cells and may light up tumors better than current scans. **You may be eligible if...** - You are over 18 years old - You have been recently diagnosed (within the past month) with pancreatic cancer that has not spread to other organs, confirmed by biopsy or cytology - You are already enrolled in a related research cohort (the HoMING study) - You are affiliated with the French social security system **You may NOT be eligible if...** - You are under legal protection (guardianship) - You are pregnant or breastfeeding - You are a woman of childbearing potential not using effective contraception Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-FAPI-46 for PET / CT scan

Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.

Locations(1)

Institut Curie -site Saint-Cloud

Saint-Cloud, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06659705

Related Trials

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

NCT0725540410 locations

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT075621523 locations

Nutrition Intervention for Pancreatic Cancer

NCT075545602 locations

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT074508591 location

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

NCT0721771710 locations